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Abstract
Background: Thrombocytosis has been associated with poor ovarian cancer prognosis. However, comparisons of
thresholds to define thrombocytosis and evaluation of relevant timing of platelet measurement has not been
previously conducted.
Methods: We selected Tumor Registry confirmed ovarian, primary peritoneal, and fallopian tube cancer cases
diagnosed between 1995–2013 from the Vanderbilt University Medical Center. Laboratory measured platelet values
from electronic medical records (EMR) were used to determine thrombocytosis at three thresholds: a platelet count
greater than 350, 400, or 450 × 109/liter. Timing was evaluated with 5 intervals: on the date of diagnosis, and up to
1, 2, 4, and 8 weeks prior to the date of diagnosis. Cox regression was used to calculate hazard ratios (HR) and
confidence intervals (CI) for association with overall survival; adjustment included age, stage, grade, and histologic
subtype of disease.
Results: Pre-diagnosis platelet measures were available for 136, 241, 280, 297, and 304 cases in the five intervals.
The prevalence of thrombocytosis decreased with increasing thresholds and was generally consistent across the
five time intervals, ranging from 44.8–53.2 %, 31.6–39.4 %, and 19.9–26.1 % across the three thresholds. Associations
with higher grade and stage of disease gained significance as the threshold increased. With the exception of the
lowest threshold on the date of diagnosis (HR350: 1.55, 95 % CI: 0.97–2.47), all other survival associations were significant,
with the highest reaching twice the risk of death for thrombocytosis on the date of diagnosis (HR400: 2.01,
95 % CI: 1.25–3.23).
Conclusions: Our EMR approach yielded associations comparable to published findings from medical record
abstraction approaches. In addition, our results indicate that lower thrombocytosis thresholds and platelet measures
up to 8 weeks before diagnosis may inform ovarian cancer characteristics and prognosis.
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Background
Ovarian cancer is a rapidly progressive and lethal dis-
ease. In the United States (US), 22,280 new cases and
14,240 deaths due to ovarian cancer are estimated to
occur [1]. Ovarian cancer is the 5th leading cause of
cancer deaths among women and is responsible for
more deaths per year than any other gynecologic malig-
nancy [1]. Because of the anatomic location within the
peritoneal cavity, ovarian cancer may be very advanced
or even distantly metastatic before a patient experiences
symptoms. Further, these symptoms are often initially
vague and non-specific, and may mimic a variety of be-
nign conditions [2]. Ovarian cancer also lacks a detect-
able pre-invasive stage that can be reliably evaluated by
screening on a population level [2]. As a result, over
60 % of ovarian cancer presents with advanced stage dis-
ease [1–3]. Recent US data indicate a dismal five year
relative survival rate of 46 %; this is reduced to 28 %
among cases with distant metastases [1].
The association between thrombocytosis and the pres-
ence of an underlying solid tumor has long been recog-
nized, prompting investigation of the role of platelets in
disease progression [4]. Platelets promote cancer cell
survival through a variety of mechanisms, including pro-
tection from immune surveillance, promotion of angio-
genesis, and arrest of the cancer cell cycle [5]. Platelets
have also been shown to increase the proliferation rate
of ovarian cancer cells indepedent of direct contact with
those cells and unaffected by blockade of adhesion re-
ceptors [6]. Molecular studies have proffered a possible
mechanism for thrombocytosis in advancing tumor
growth. Tumor derived interleukin-6 increases hepatic
thrombopoietin, which stimulates bone marrow mega-
karyocytes and platelet production of TGF-β1, which in
turn activates the TGF-β1/smad proliferation pathway in
tumor cells [7]. Additionally, in vitro knockdown of
TGF-βR1 in ovarian cancer cells by an anti-TGF-βR1
antibody halts proliferation of cancer cells when exposed
to platelets [6]. Using an orthotopic mouse model of
ovarian cancer, platelet transfusion resulted in increased
tumor growth, and platelets were demonstrated to pro-
tect cancer cells from apoptosis [8]. The persistent para-
crine cycle in which platelets promote tumor cell
proliferation and sustain cancer cell viability may under-
lie differences in cancer prognosis according to platelet
count.
The majority of ovarian malignancies are epithelial,
which has worse survival than other ovarian tumors [3].
Known prognostic factors for epithelial ovarian cancer
include age, stage, grade histologic subtype, and optimal
cytoreduction [7, 9, 10]. In addition, pre-diagnosis throm-
bocytosis has been associated with poor prognosis [7–9,
11–19]. To date, more than ten studies have evaluated the
prognostic significance of preoperative thrombocytosis in
ovarian cancer [7–9, 11–20]; all but one found that
thrombocytosis was an independent negative factor in
ovarian cancer survival [20]. However, the diagnostic
threshold used to define thrombocytosis has varied from
300 to 450 × 109/liter (L). Further, studies have used vari-
ous time intervals for platelet measurements relative to
diagnosis. Because of a lack of uniformity in thresholds
and timing of platelet counts used to evaluate the associ-
ation between thrombocytosis and overall survival in the
existing literature, this study was undertaken to systemat-
ically compare three thresholds for thrombocytosis and
the relevant timing of pre-diagnosis platelet counts in rela-
tion to ovarian cancer survival using Tumor Registry con-




Appropriate Institutional Review Board (IRB) approval
was garnered for this retrospective cohort study of de-
identified EMR data (Vanderbilt University IRB #121299).
Primary ovarian, peritoneal, and fallopian tube cancer
cases were selected by International Classification of
Disease-Oncology (ICD-O) codes C569 and C570 from
the VUMC Tumor Registry (Fig. 1). Cases diagnosed be-
fore 1980, after 2013, or with unkown dates of diagnosis
were excluded (N= 40). Germ cell tumors (ICD-O 9060,
9064, 9071, 9080, 9082, 9084, 9085), sex-cord stromal tu-
mors (ICD-O 8620, 8634, 8640, 8670), and other tumors
(ICD-O 8240, 8243, 8800, 8802, 8890, 8910, 9500, 9680)
were excluded (N= 70). Epithelial ovarian cancer (EOC)
cases were classified by histologic subtype: serous/papil-
lary (ICD-O codes 8050, 8260, 8441, 8442, 8450, 8451,
8460, 8461, 8462); mucinous (ICD-O codes 8470, 8471,
8472, 8473, 8480, 8490); endometrioid (ICD-O codes
8380), clear cell (ICD-O codes 8310, 8313); and other
(ICD-O codes 8013, 8041, 8046, 8070, 8120, 8320, 8570,
8950, 8951, 8980, 9000). Ovarian cancer cases with un-
known histologic subtypes (ICD-O codes 8000, 8010,
8020, 8021, 8140, 8143, 8255, 8323, 8410, 8440, 8560)
were retained, as the majority was likely to be epithelial.
In addition to primary tumor site and histologic subtype,
Tumor Registry data included date of diagnosis, stage, and
grade of disease; women determined to have an age at
diagnosis of less than 18 were excluded (N= 27). Women
who had a prior epithelial or invasive carcinoma other
than ovarian (N= 15), history of a myeloproliferative or
myelodysplastic disorder (N= 2), or an autoimmune or in-
flammatory disorder (N= 10) were also excluded from
analysis; no patients were found to have a history of total
splenectomy (ICD code 41.5) prior to ovarian cancer
diagnosis.
Laboratory values for pre-diagnosis platelet counts
were selected from the Synthetic Derivative (SD), a de-
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identified mirror of electronic medical records (EMR)
from VUMC. Platelet count measurements (Current
Procedural Terminology (CPT) code 85049) were from
Sysmex assays conducted on whole blood samples with
a reference range of 135–370 × 109/L by the Vanderbilt
Pathology Lab Service. Thrombocytosis was defined
using three thresholds: platelet counts greater than 350,
400, or 450 × 109/L. The relevant time frame of platelet
measurement was evaluated with 5 time intervals: on
the date of diagnosis, and up to 1 week, 2 weeks,
4 weeks, 8 weeks before and including the date of diag-
nosis. Only pre-diagnosis platelet counts were analyzed,
as paraneoplastic mechanisms are thought to drive throm-
bocytsosis [7]. Further, post-operative platelet measures
are intrinsically altered by inflammation secondary to sur-
gical stress, and can be iatrogenically changed by transfu-
sion or blood loss during debulking surgery for ovarian
cancer [21, 22]. Death from any cause was determined
from EMR and by linkage to the National Death Index
(NDI). Cases were considered to have died if they were
listed as deceased in the SD or if there was a date of death
from the NDI. Otherwise, overall survival was censored at
the date of last EMR entry.
Statistical analysis
Differences in clinical and histologic characteristics be-
tween cases with and without thrombocytosis were ex-
amined with Student’s t tests, χ2 tests, and Fisher’s exact
test as appropriate. Cox proportional hazards regression
was used to derive hazard ratios (HRs) and 95 % confi-
dence intervals (CIs) for associations between thrombo-
cytosis and overall ovarian cancer survival. Calendar
time was used as the time scale for Cox regression
models, with entry at date of ovarian cancer diagnosis
and exit at date of death or last EMR entry. Due to low
numbers, survival times were truncated at 10 years to
prevent unstable estimates. Regression models included
adjustment for known prognostic factors, including age
at diagnosis, stage, grade, and histologic subtype of
disease. Survival functions were visualized with Kaplan-
Meier plots; the log-rank test was used to assess if differ-
ences were significant. Manual review of EMR was
conducted to validate the date of diagnosis and timing of
platelet measurement for a subset of cases. Sensitivity
analyses were conducted by excluding cases with low
malignant potential (LMP) tumors, synchronous cancers,
non-White cases, and those with unknown stage of dis-
ease or histologic subtype. Data preparation was con-
ducted with Excel and Python. In Python, the csv,
datetime, time, matplotlib, and numpy modules were used
along with dictionary and list stat structures to sort and
filter data by platelet count and date relative to diagnosis
date. All analyses were performed using SAS version 9.4
(SAS Institute, Cary, NC). A two-sided probability of 0.05
was used to determine statistical significance.
Results
Table 1 presents the demographic and histopathologic
characteristics of 1,170 Tumor Registry confirmed cases
diagnosed between 1980 and 2013, and 304 cases with
pre-diagnostic platelet measures available from the
VUMC SD. No cases diagnosed before 1995 were found
to have laboratory measured platelet values available in
their EMR. Although age at diagnosis, primary site, and
histologic subtype were generally comparable, fewer
cases with platelet count measures available had either
Fig. 1 Flow Chart of Tumor Registry and Platelet Lab Data Preparation of de-identified Electronic Medical Records from the Vanderbilt University
Medical Center
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unknown or unstaged disease (8.22 vs. 27.78 %) or un-
known grade (27.63 vs. 38.97 %) than all cases. Among
cases with pre-diagnosis platelet measures available, the
majority were white (N = 266, 87.5 %), and had
advanced stage (III or IV, N = 191, 62.83 %), high grade
(poorly differentiated or undifferentiated, N = 155,
51.0 %), and serous histologic subtypes (N = 147,
48.4 %) of disease.
Table 1 Clinical Characteristics of Tumor Registry Confirmed Ovarian Cancer Cases from the Vanderbilt University Medical Center
All Epitheilal or Unknown Cases (N = 1170) Cases With Pre-Diagnosis Platelets Measured (N = 304)
Characteristic N or mean % or std deva N or mean % or std deva
Age at Diagnosis, years 58.5 13.7 60.2 14.5




1995–1999 202 17.3 62 20.4
2000–2004 199 17.0 83 27.3
2005–2009 208 17.8 100 32.9
2010–2013 118 10.1 59 19.4
Race
White 1036 88.6 266 87.5
Black 68 5.8 25 8.2
Asian 11 0.9 2 0.7
Native 2 0.2 0 0.0
Other/Unknown 53 4.5 11 3.6
Primary Site
Ovary (C569) 1129 96.5 294 96.7
Fallopian Tube (C570) 41 3.5 10 3.3
Histologic Subtype
Serous 666 56.9 147 48.4
Endometrioid 105 9.0 33 10.9
Mucinous 75 6.4 24 7.9
Clear Cell 45 3.9 15 4.9
Other 47 4.0 18 5.9
Unknown 232 19.8 67 22.0
Stage of Disease
I 172 14.7 69 22.7
II 52 4.4 19 6.3
III 360 30.8 124 40.8
IV 261 22.3 67 22.0
Unknown/Unstaged 325 27.8 25 8.2
Disease Grade
1, Well differentiated 58 5.0 21 6.9
2, Moderately differentiated 161 13.8 44 14.5
3, Poorly differentiated 412 35.2 120 39.5
4, Undifferentiated 83 7.1 35 11.5
Unknown 456 39.0 84 27.6
Overall Survival, years 4.1 3.4 3.4 3.1
aPercentages may not sum to 100 due to rounding error
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Associations between thrombocytosis and clinical co-
variates are summarized in Table 2. When using the
lowest thrombocytosis threshold, associations with
higher stage (P-value =0.051) and grade (P-value =0.115)
were suggestive, but not significant. Using either of the
higher thresholds, cases were more likely to have stage
IV or unstaged disease (P-value400 = 0.038, and
P-value450 = 0.009) and undifferentiated grade 4 tumors
(P-value400 = 0.008, and P-value450 = 0.010) than cases
without thrombocytosis. A significant association was seen
with primary site at the middle threshold (P-value400 =
0.015), but this did not evident at either of the other
thresholds. Regardless of threshold used, there was no as-
sociation between thrombocytosis and age, race, or histo-
logic subtype of disease.
In Table 3, associations between thrombocytosis and
overall ovarian cancer survival are shown, including 5
time intervals and three thresholds. Within each thresh-
old, the prevalence of thrombocytosis was lowest on the
date of diagnosis, but this was not found to significantly
differ from the other timeframes. In both unadjusted
and multivariable adjusted analysis, thrombocytosis was
Table 2 Associations Between Thrombocytosis within 8 Weeks of Diagnosis and Clinical Covariates among Ovarian Cancer Cases
from the Vanderbilt University Medical Center
Thrombocytosis (>350 × 109/L) Thrombocytosis (>400 × 109/L) Thrombocytosis (>450 × 109/L)
No (N = 145) Yes (N = 159) No (N = 190) Yes (N = 114) No (N = 228) Yes (N = 76)
Characteristic N or mean (% or std dev)a P-value** N or mean (% or std dev)a P-value** N or mean (% or std dev)a P-value**
Age at Diagnosis, years 60.7 (14.1) 59.9 (14.8) 0.631 60.9 (14.3) 59.1 (14.8) 0.275 60.4 (14.4) 59.8 (14.8) 0.746
Race
White 128 (88.3) 138 (86.8) 0.696 169 (89.0) 97 (85.1) 0.325 202 (88.6) 64 (84.2) 0.317
Other/Unknown 17 (11.7) 21 (13.2) 21 (11.1) 17 (14.9) 26 (11.4) 12 (15.8)
Primary Site
Ovary (C569) 137 (94.5) 157 (98.7) 0.052 † 114 (100.0) 114 (100.0) 0.015 † 218 (95.6) 76 (100.0) 0.072 †
Fallopian Tube (C570) 17 (5.5) 2 (1.3) 0 (0.0) 0 (0.0) 10 (4.4) 0 (0.0)
Histologic Subtype
Serous 68 (46.9) 79 (49.7) 0.691 88 (46.3) 59 (51.8) 0.629 111 (48.7) 36 (47.4) 0.414
Endometrioid 14 (9.7) 19 (12.0) 20 (10.5) 13 (11.4) 24 (10.5) 9 (11.8)
Mucinous 15 (10.3) 9 (5.7) 19 (10.0) 5 (4.4) 22 (9.7) 2 (2.6)
Clear Cell 6 (4.1) 9 (5.7) 9 (4.7) 6 (5.3) 10 (4.4) 5 (6.6)
Other 9 (6.2) 9 (5.7) 11 (5.8) 7 (6.1) 12 (5.3) 6 (7.9)
Unknown 33 (22.8) 34 (21.4) 43 (22.6) 24 (21.1) 49 (21.5) 18 (23.7)
Serous 68 (46.9) 79 (49.7) 0.888 88 (46.3) 59 (51.8) 0.646 111 (48.7) 36 (47.4) 0.923
Non-Serous 44 (30.3) 46 (28.9) 59 (31.1) 31 (27.2) 68 (29.8) 22 (29.0)
Unknown 33 (22.8) 34 (21.4) 43 (22.6) 24 (21.1) 49 (21.5) 18 (23.7)
Stage of Disease
I 43 (29.7) 26 (16.4) 0.051 52 (27.4) 17 (14.9) 0.038 59 (25.9) 10 (13.2) 0.009
II 10 (6.9) 9 (5.7) 14 (7.4) 5 (4.4) 17 (7.5) 2 (2.6)
III 56 (38.6) 68 (42.8) 76 (40.0) 48 (42.1) 94 (41.2) 30 (39.5)
IV 25 (17.2) 42 (26.4) 35 (18.4) 32 (28.1) 43 (18.9) 24 (31.6)
Unknown/Unstaged 11 (7.6) 14 (8.8) 13 (6.8) 12 (10.5) 15 (6.6) 10 (13.2)
Disease Grade
1, Well differentiated 10 (6.9) 11 (6.9) 0.115 15 (7.9) 6 (5.3) 0.008 18 (7.9) 3 (4.0) 0.010
2, Moderately
differentiated
21 (14.5) 23 (14.5) 29 (15.3) 15 (13.2) 36 (15.8) 8 (10.5)
3, Poorly differentiated 57 (39.3) 63 (39.6) 78 (41.1) 42 (36.8) 90 (39.5) 30 (39.5)
4, Undifferentiated 10 (6.9) 25 (15.7) 12 (6.3) 23 (20.2) 18 (7.9) 17 (22.4)
Unknown 47 (32.4) 37 (23.3) 56 (29.5) 28 (24.6) 66 (29.0) 18 (23.7)
aPercentages may not sum to 100 % due to rounding error
**P-values from χ2 test or Fisher’s exact test where indicated (†); bold values denote significant associations
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significantly associated with worse survival across all five
time intervals and three thresholds, except for the lowest
threshold on the date of diagnosis (P-value350crude =
0.093 and P-value350adjusted = 0.070). Other associations
at this threshold indicated a 79-83 % significantly in-
creased risk of death with thrombocytosis. For both of
the higher thresholds, associations were larger on the
date of diagnosis (HR400: 2.01, 95 % CI 1.25–3.23, and
HR450: 2.00, 95 % CI: 1.16–3.46), and smaller as time to
diagnosis increased up to 8 weeks (HR400: 1.55, 95 % CI:
1.14–2.10, and HR450: 1.55, 95 % CI: 1.12–2.15). Kaplan-
Meier analysis was found to be in general agreement,
such that ovarian cancer cases with pre-diagnostic
thrombocytosis were found to have significantly shorter
survival across the 400 threshold regardless of timing,
and significantly shorter survival for the 350 and 450
thresholds for all time periods except for those taken on
the date of diagnosis (data not shown).
To validate dates of platelet measurement and diagno-
sis, EMR were manually reviewed for twenty cases. The
Tumor Registry date of diagnosis matched the date of
operative and/or pathology report for 75 % of reviewed
cases. However, for 25 %, the Tumor Registry date of
diagnosis was up to 2 weeks before the operative and/or
pathology report, and usually coincided with the first
presentation of symptoms that led to the diagnosis, e.g.,
computed tomography (CT) or ultrasound imaging.
Based on this, we selected 2 weeks prior to and includ-
ing the date of diagnosis as the interval most likely to
best capture pre-diagnosis thrombocytosis in our data,
and used this to conduct sensitivity analyses (Table 4).
In agreement with our primary analysis, excluding cases
with low malignant potential (N= 12), synchronous can-
cers (N = 26), not reported as White (N= 38), or un-
known stage of disease (N= 36), did not materially alter
our results. When unknown histologic subtypes (N = 86)
were excluded, significance was attenuated for two of
the three thresholds (P-value350 = 0.034; P-value400 =
0.089; P-value450 = 0.186). When all above exclusions
were simultaneously applied, all associations were attenu-
ated (P-value350 = 0.065; P-value400 = 0.072; P-value450 =
0.096), likely due to the small sample size remaining
in the analysis (N = 152). Similar to Cox regression,
Kaplan-Meier plots showed significant differences for
cases with and without thrombocytosis within two weeks
of diagnosis for all three thresholds evaluated (Fig. 2).
Discussion
In this large retrospective analysis of confirmed Tumor
Registry cases from a single tertiary-care medical center
with platelet measurments available in electronic med-
ical records (EMR), we found that thrombocytosis,
Table 3 Thrombocytosis and Overall Survival Among Ovarian Cancer Cases from the Vanderbilt University Medical Center
Thrombocytosis No Thrombocytosis
(Reference)
Unadjusted Association Multivariable Associationa
Thrombocytosis % N Cases N Events N Cases N Events HR 95 % CI P-value* HR 95 % CI P-value*
Defined by ≥350 × 109/L
Date of diagnosis 44.8 61 42 75 46 1.45 0.94–2.23 0.093 1.55 0.97–2.47 0.070
1 week prior to date of diagnosis 53.1 128 96 113 63 2.09 1.51–2.89 <0.001 1.83 1.30–2.58 0.001
2 week prior to date of diagnosis 52.5 147 106 133 72 1.96 1.47–2.66 <0.001 1.79 1.31–2.44 <0.001
4 week prior to date of diagnosis 53.2 158 110 139 73 1.94 1.44–2.62 <0.001 1.80 1.33–2.45 <0.001
8 week prior to date of diagnosis 52.3 159 111 145 77 1.92 1.43–2.58 <0.001 1.80 1.33–2.43 <0.001
Defined by ≥400 × 109/L
Date of diagnosis 31.6 43 33 93 60 1.98 1.27–3.09 0.003 2.01 1.25–3.23 0.004
1 week prior to date of diagnosis 39.4 95 73 146 94 1.92 1.39–2.64 <0.001 1.62 1.16–2.26 0.005
2 week prior to date of diagnosis 38.2 107 79 173 108 1.87 1.39–2.53 <0.001 1.60 1.17–2.18 0.003
4 week prior to date of diagnosis 38.1 113 80 184 112 1.78 1.32–2.40 <0.001 1.54 1.14–2.09 0.006
8 week prior to date of diagnosis 37.5 114 81 190 116 1.78 1.33–2.40 <0.001 1.55 1.14–2.10 0.005
Defined by ≥450 × 109/L
Date of diagnosis 19.9 27 22 109 71 1.98 1.21–3.27 0.007 2.00 1.16–3.46 0.013
1 week prior to date of diagnosis 26.1 63 51 178 116 2.01 1.43–2.82 <0.001 1.71 1.20–2.45 0.003
2 week prior to date of diagnosis 25.7 72 55 208 132 1.91 1.38–2.65 <0.001 1.62 1.16–2.27 0.005
4 week prior to date of diagnosis 24.9 74 56 223 136 1.88 1.37–2.59 <0.001 1.56 1.12–2.17 0.008
8 week prior to date of diagnosis 25.0 76 57 228 140 1.79 1.30–2.45 <0.001 1.55 1.12–2.15 0.009
*Bold type denotes significant associations
aAdjusted for age at diagnosis, stage, grade, and histologic subtype
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Table 4 Sensitivity Analysis of Thrombocytosis within 2 Weeks of Diagnosis and Overall Ovarian Cancer Survival
Thrombocytosis No Thrombocytosis Unadjusted Association Multivariable Associationa
Thrombocytosis N Cases N Events N Cases N Events HR 95 % CI P-value* HR 95 % CI P-value*
Defined by ≥350 × 109/L
2 weeks to date of diagnosis 147 106 133 72 1.96 1.45–2.66 <0.001 1.78 1.31–2.44 <0.001
Excluding low malignant potential tumors 147 106 121 71 1.71 1.26–2.32 <0.001 1.67 1.22–2.28 0.001
Excluding synchronous cancers 134 101 124 71 1.94 1.42–2.64 <0.001 1.72 1.26–2.36 <0.001
Excluding non–Whites 128 91 114 61 1.92 1.38–2.68 <0.001 1.88 1.34–2.62 <0.001
Excluding unknown stage of disease 134 95 124 67 1.89 1.37–2.60 <0.001 1.66 1.20–2.30 0.002
Excluding unknown histologic subtypes 115 79 104 52 1.81 1.27–2.58 0.001 1.48 1.03–2.13 0.034
Excluding all of the above cases 84 60 68 40 1.47 0.98–2.20 0.063 1.47 0.98–2.21 0.065
Defined by ≥400 × 109/L
2 weeks to date of diagnosis 107 78 173 100 1.87 1.39–2.53 <0.001 1.60 1.17–2.18 0.003
Excluding low malignant potential tumors 107 78 161 99 1.67 1.23–2.26 <0.001 1.50 1.10–2.06 0.010
Excluding synchronous cancers 96 74 162 98 1.94 1.42–2.64 <0.001 1.61 1.17–2.20 0.003
Excluding non–Whites 91 64 151 88 1.75 1.26–2.43 <0.001 1.58 1.13–2.21 0.008
Excluding unknown stage of disease 96 69 162 93 1.84 1.34–2.52 <0.001 1.49 1.08–2.07 0.016
Excluding unknown histologic subtypes 84 59 135 72 1.81 1.28–2.57 <0.001 1.37 0.95–1.97 0.089
Excluding all of the above cases 59 44 93 56 1.69 1.13–2.53 0.011 1.46 0.97–2.20 0.072
Defined by ≥450 × 109/L
2 weeks to date of diagnosis 72 55 208 123 1.91 1.38–2.65 <0.001 1.62 1.16–2.27 0.005
Excluding low malignant potential tumors 72 55 196 122 1.73 1.25–2.39 <0.001 1.53 1.09–2.14 0.014
Excluding synchronous cancers 64 51 194 121 1.92 1.38–2.68 <0.001 1.66 1.17–2.34 0.004
Excluding non–Whites 60 44 182 108 1.82 1.27–2.61 0.001 1.65 1.14–2.40 0.008
Excluding unknown stage of disease 63 47 195 115 1.88 1.33–2.65 <0.001 1.51 1.05–2.15 0.024
Excluding unknown histologic subtypes 54 41 165 90 1.81 1.24–2.63 0.002 1.31 0.88–1.94 0.186
Excluding all of the above cases 37 29 115 71 1.73 1.11–2.70 0.016 1.49 0.93–2.37 0.096
*Bold type denotes significant associations
aAdjusted for age at diagnosis, stage, grade, and histologic subtype as appropriate after exclusions
Fig. 2 Ovarian Cancer Overall Survival Kaplan-Meier functions for Thrombocytosis within two weeks of diagnosis.; Legend: a Thrombocytosis (350)
two weeks prior to and including the date of diagnosis; b Thrombocytosis (400) two weeks prior to and including the date of diagnosis; and
c Thrombocytosis (450) two weeks prior to and including the date of diagnosis
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defined as a platelet count greater than 350, 400, or
450 × 109/L, and measured up to 8 weeks before diagno-
sis, was associated with significantly shorter overall ovar-
ian cancer survival. This work adds to existing literature
by providing a comprehensive comparison of thrombo-
cytosis prevalence and associations with survival across
three thresholds with uniform platelet measures in one
study population, and indicates that elevated platelet
counts up to eight weeks before diagnosis may be in-
formative for ovarian cancer prognosis. In addition, this
research demonstrates the power of combining Tumor
Registry and EMR data to evaluate potential prognostic
factors as an alternate approach to analysis based on
data from retrospective medical chart review.
To date, more than ten studies have analyzed pre-
operative thrombocytosis in relation to ovarian cancer
survival [7–9, 11–17, 19, 20]. The threshold to define
thrombocytosis has varied from 300–450, with most
studies using 400 [11–15, 17–20]. The relevant timing
of thrombocytosis has also varied from within 1 week
[12, 13, 18], to within 2 weeks from the date of diagnosis
[14, 15, 19], although several publications lack specific
details on timing other than qualifying measures as pre-
operative [8, 9, 11, 16, 20]. The prevalence of throm-
bocytosis has varied across studies, with ranges of
22.4 % [14] to 43.5 % [19]. Among those with signifi-
cant associations with overall ovarian cancer survival,
hazards have also ranged considerably. The largest as-
sociation reported was a nearly five-fold increased risk
of death among 136 cases, where adjustment included
age, stage, histologic subtype, grade, cytoreduction,
chemotherapy, CA-125, and fibrinogen [18]. In that
study, the thrombocytosis threshold differs between
the text (400) and table of results (300), but the re-
ported prevalence was low (7.4 %) [18]. The largest
study to date included 816 cases and had a preva-
lence of 22.8 % with a threshold of 400 [11]. After
adjusting for age, menopausal status, histologic sub-
type, grade, stage, residual disease, ascites, CA-125,
hemoglobin, and leukocyte count, cases with thrombocy-
tosis had a more than two-fold higher risk of death [11].
The highest prevalence reported (42.9 %) used a threshold
of 350 among 91 cases; after adjustment for age, meno-
pausal status, stage, CA-125, and surgery, thrombocytosis
was associated with a more than two-fold increased risk of
death [16]. Meta-analysis of 5 studies with different statis-
tical adjustments, but all using 400 as their threshold,
yielded a thrombocytosis prevalence of 31.1 %, and a 52 %
significantly increased risk of 5 year mortality [23]. Thus,
our findings for the prevalence of pre-diagnosis thrombo-
cytosis and associations with overall survival are in general
agreement with existing literature, indicating that evalu-
ation of VUMC Tumor Registry confirmed cases is a vi-
able approach for ovarian cancer research.
Pre-operative thrombocytosis has been linked to de-
creased overall survival and to a host of clinical parame-
ters and outcomes, which may in turn help elucidate the
factors at play in increased mortality for those patients
with thrombocytosis. Platelets are an acute phase react-
ant, meaning that platelet count transiently increases in
response to inflammation [24]. Etiologies for reactive
thrombocytosis include malignancy, tissue damage,
infection, and chronic inflammation [22]. Factors influ-
encing platelet count, in the absence of the the afore-
mentioned reactive factors, include age, sex, race/
ethnicity, nutritional status, drug exposure [24, 25], and
inherent genetic variability [26]. Thrombocytosis in pa-
tients with ovarian cancer is associated with greater
volumes of ascites [6, 13, 18], lower hemoglobin, re-
ceipt of peri-operative packed red blood cells transfu-
sion [6], major post-operative complications [27] and
post-operative death [25]. Thrombocytosis with concur-
rent leukocytosis, another marker of inflammation or
infection, was associated with a higher risk of post-
operative death (OR 5.4) than either thrombocytosis
(OR 2.16) or leukocytosis alone (OR 1.78) [27].
Furthermore, pre-operative thrombocytosis was an
independent negative prognostic factor for disease re-
currence and progression-free survival [5, 6, 9, 12, 15–
17, 19]. Taken together, these factors may explain, at
least in part, the association between thrombocytosis
and shorter overall survival.
In addition to overall mortality, pre-operative throm-
bocytosis was found to be an independent predictor for
the development of venous thromboembolism among
clear cell ovarian carcinoma cases [28]. Risk factors for
venous thromboembolism in ovarian cancer include in-
creasing age, a higher number of chronic comorbid con-
ditions, higher stage disease, invasive histology, and the
absence of any major surgery [29]. In a multivariable
model, women with symptomatic venous thrombo-
embolism at the time of diagnosis prior to primary treat-
ment had significantly shorter overall survival when
compared with women without venous thromboembol-
ism at diagnosis [30]. In accordance with the guidelines
provided by the American Society of Clinical Oncology,
oncology patients should receive venous thromboembol-
ism prophylaxis 7–10 days prior to a major operation
and extending up to 4 weeks post-operatively in patients
with abdominal or pelvic surgery with high risk features
[31]. As our data indicate that thrombocytosis up to
8 weeks pre-operative may confer worse survival, and
thrombocytosis has been linked to development of ven-
ous thromboembolism, more investigation is needed to
determine the possible efficacy of longer periods of pre-
operative thromboembolism prophylaxis in helping to
reduce ovarian cancer morbidity and mortality. Robust
findings from our sensitivity analysis results indicate that
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pre-operative prophylaxis may have clinical utility for all
types of ovarian cancer cases.
This study expands upon existing knowledge by dir-
ectly comparing three thresholds for thrombocytosis. As
expected, the prevalence of thrombocytosis decreased
with increasing threshold. For both the 400 and 450
thresholds, we found significant associations with higher
stage and grade of disease, and significant associations
with overall survival even after adjusting for clinical and
tumor characteristics. Our study also expands upon
current knowledge by analyzing multiple time widows
for the occurrence of thrombocytosis. For each thresh-
old, the prevalence of thrombocytosis was lowest on the
date of diagnosis, and was fairly consistent across the
remaining time frames. With regard to survival associa-
tions, when using the smallest threshold of 350, the as-
sociation on the date of diagnosis was not significant,
but increasing time frames all had significant associa-
tions with worse survival. This pattern differed for both
of the larger thresholds, where stronger associations oc-
curred on the date of diagnosis, and smaller, but still sig-
nificant associations, were found when measures up to
8 weeks pre-diagnosis were included. Larger associations
closer to the date of diagnosis may be due to disease pro-
gression and subsequent worsening paraneoplastic throm-
bocytosis. Alternately, inclusion of values up to 8 weeks
pre-diagnosis may increase measurement error, such that
cases with thrombocytosis initially evaluated for a separate
indication may have resolution of thrombocytosis by the
time of cancer diagnosis. Such misclassification of a di-
chotomous exposure would be independent of the out-
come and would therefore serve to attenuate associations
toward the null. Notably, our validity sub-study indicated
that all platelet measures were from before diagnosis. In
addition, we found that among cases with thrombocytosis
occurring within 8 weeks of diagnosis, more than 95 %
also had thrombocytosis within 4 weeks, 2 weeks, or
1 week of diagnosis, regardless of the threshold. Only
when evaluating the smallest timeframe, the date of diag-
nosis, was this reduced to 70 % of cases. Thus, misclassifi-
cation of thrombocytosis is not likely to greatly influence
the results of the current study.
Limitations of this investigation include the number of
cases with preoperative platelet count data available,
when compared with all confirmed Tumor Registry
cases. Differences in disease presentation, preoperative
course, and time to diagnosis likely contribute to vari-
ability in whether platelets were measured before or
after diagnosis for each patient. Data on use of anti-
platelet or anti-coagulant medications, which may alter
the potential for adverse events in the setting of throm-
bocytosis, was not included in this study. Further, many
cases were missing information on histologic subtype,
stage, or grade of disease. Sensitivity analyses conducted
by excluding these cases still yielded mostly significant
survival associations, indicating that missing data is not
greatly impacting our findings. Another limitation is the
lack of data on optimal tumor cytoreduction, which has
been shown to be an important negative predictor of
ovarian cancer survival [10]. However, thrombocytosis
has not been found to be associated with optimal
debulking in prior studies, so this should not confound
the current results. While sucessess of surgical debulking
was unavailable from Tumor Registry data, all included
cases were reviewed by trained Tumor Registry personnel,
and information on stage, grade, and subtype of disease
were reasonably standardized. Additional limitations of
this analysis include the inherent retrospective nature of
our analysis, the possibility of including deaths unrelated
to ovarian cancer by use of all-cause mortality, and care
limited to a single tertiary care center. Thus, our findings
may not be generalizable to all ovarian cancer cases at all
institutions. However, outcomes were ascertained by link-
age to the NDI as well as by EMR notes on vital status,
and our results are generally in agreement with those from
other single and multi-center studies. Additional strengths
of the current study include a robust analytic approach
that included three thrombocytosis thresholds, explor-
ation of relevant time frames for platelet measurement,
and multivariable adjustment for all clinical covariates
available. In addition, our study employed compuater pro-
gramming methods to obtain EMR data, which differs
from other studies in which manual chart review was con-
ducted. Rather than including cases without evidence of
thrombocytosis noted in medical records, our reference
group included only cases where platelet values were actu-
ally measured, and were not found to be elevated.
Conclusions
Thrombocytosis was identified in 20-50 % of ovarian
cancer cases, depending upon the pre-diagnostic time
interval and diagnostic threshold. Regardless of timing
or threshold, thrombocytosis was generally associated
with more aggressive tumor characteristics and was an
independent negative prognostic factor for overall sur-
vival. Our findings indicate that lower thrombocytosis
thresholds and measures collected up to 8 weeks before
diagnosis may inform ovarian cancer prognosis.
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